美股異動 | 黑石(BX.US)盤前漲1% 與賽諾菲合作開發多發性骨髓瘤療法
格隆匯3月15日丨黑石(BX.US)盤前漲1.32%,報110.2美元,總市值802億美元。
賽諾菲(SNY.US)和黑石日前宣佈,雙方將開展一項風險分擔合作,根據合作協議,黑石旗下Blackstone Life Sciences將提供高達3億歐元的資金,以加速用於治療多發性骨髓瘤患者的CD38抗體Sarclisa的研究和臨牀開發項目。如果項目成功,Blackstone Life Sciences將有資格從該療法的皮下製劑未來銷售中獲得提成費。Sarclisa皮下製劑的臨牀試驗將於下半年開始。Sarclisa已經獲得監管部門的批准,用於靜脈注射治療某些多發性骨髓瘤患者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.